Bone Biologics Corp (BBLG) Fair Value 2026

BBLG · Orthopedic, Prosthetic & Surgical Appliances & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.6 /10

32 fundamental signals · 6 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-07-15, Bone Biologics Corp (BBLG) trades at $1.24, approximately 29% below CirclFi’s Bayesian DCF fair value of $1.75. QOC: 3.6/10. Value Trap Risk: 24/100 (SAFE). 6/13 models active.

Key Facts

Ticker
BBLG
Price
$1.24
Quality Score
3.6/10
Value Trap Risk
24/100
Models Active
6/13
Last Updated
Strength: First Chicago suggests +247.2% upside with 14% confidence
Risk: Below-average Quality Score of 3.6/10 signals weak fundamentals

Is Bone Biologics Corp (BBLG) Undervalued or Overvalued in 2026?

According to CirclFi’s 6-model valuation engine, Bone Biologics Corp (BBLG) appears undervalued as of : the median of 6 independent fair value estimates is $2.83, 128.1% above the current price of $1.24. Estimates range from $0.30 to $4.30. BBLG scores 3.6/10 on fundamental quality and 24/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Bone Biologics Corp Stock in 2026? →

Valuation Matrix

6 Intrinsic Value Models vs. Current Price ($1.24)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $1.75 +41.1%
CUCE Ensemble
Low Conviction
 $3.91 +215.1%
First Chicago
Low Conviction
 $4.30 +247.2%

Unlock the Full Matrix

Access 3 additional models including ML-RIV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 6 Models →

Cancel anytime · No contracts · Instant access

What Is Bone Biologics Corp (BBLG) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Bone Biologics Corp. Trading at $1.24 against an estimated intrinsic value of $2.63, 5 of 6 active models flag meaningful upside of +112.1% on average. The most optimistic model, First Chicago, places fair value at $4.30 (+247.2%), while ML-RIV — the most conservative — estimates $0.30 (-75.6%). This +322.7% gap reflects genuine analytical uncertainty about Bone Biologics Corp's intrinsic worth.

What Do the Models Say About BBLG?

6 of 13 models are currently active for BBLG. Of these, 5 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates BBLG's intrinsic value at $1.75, implying +41.1% upside from the current price. See which stocks rank higher →

How Does BBLG Rank in Orthopedic, Prosthetic & Surgical Appliances & Supplies?

Among 25 Orthopedic, Prosthetic & Surgical Appliances & Supplies stocks, BBLG ranks #23 by Quality of Company score. CirclFi's QOC score of 3.6/10 evaluates 32 fundamental signals. A score of 3.6 signals below-average fundamentals.

Bone Biologics Corp operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BBLG a Value Trap?

CirclFi's Value Trap algorithm assigns BBLG a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

6 of 13 models are active for Bone Biologics Corp. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Bone Biologics Corp's fundamental quality profile registers 3.6/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +322.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BBLG valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BBLG's 6 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bone Biologics Corp Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Orthopedic, Prosthetic & Surgical Appliances & Supplies Stocks Should You Also Analyze?

8 related Orthopedic, Prosthetic & Surgical Appliances & Supplies stocks with 13-model coverage

STESTERIS plc (Ireland)QOC 9.7ISRGIntuitive Surgical, Inc.QOC 9.5EWEdwards Lifesciences CorporatioQOC 8.9MSAMSA Safety IncorporatedQOC 8.8CDRECadre Holdings, Inc.QOC 8.3SNNSmith & Nephew SNATS, Inc.QOC 8.2SPAISafe Pro Group Inc.QOC 7.1ESTAEstablishment Labs Holdings IncQOC 7.1

Read investment analysis: STE · ISRG · EW · MSA · CDRE

Frequently Asked Questions About Bone Biologics Corp

What is Bone Biologics Corp's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Bone Biologics Corp (BBLG) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $1.75. The Quality of Company score is 3.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BBLG overvalued or undervalued right now?

At $1.24, 5 of 6 active models suggest BBLG may be undervalued, while 1 indicate potential overvaluation. The median of all 6 fair value estimates is $2.83, 128.1% above the current price of $1.24 — a consensus view that BBLG is undervalued. The assessment depends on which methodology best fits Bone Biologics Corp's business model in Orthopedic, Prosthetic & Surgical Appliances & Supplies.

What does a Quality of Company score of 3.6 mean for BBLG?

Bone Biologics Corp's QOC of 3.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BBLG?

CirclFi analyzes BBLG with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 6 of 13 are active for this stock. Read the full methodology →

Is BBLG a value trap in 2026?

Bone Biologics Corp's Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 6-model valuation engine, Bone Biologics Corp (BBLG) has a median fair value of $2.83 — 128.1% above the current price of $1.24 — as of 2026-07-15.” Source: circlfi.com/stock/BBLG/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 6 mathematical frameworks give you clarity on BBLG.

Unlock All 6 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access